FIRST TRACKS BIOTHERAPEUTICS INC (TRAX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$40.46-4.82%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TRAX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -29.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
TRAX — earnings miss
Dated 2026-08-12
Results of Operations and Financial Condition. On August 12, 2026, First Tracks Biotherapeutics, Inc. (“First Tracks”) issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchang…
Why it matters: Finishing this trial will show progress in treating eosinophilic esophagitis. This is key for the company's plans.
Supportive ifThe Phase 1b trial in eosinophilic esophagitis will finish. Data will be released in mid-2027.
Worry ifTrial is delayed or results are inconclusive.
Why it matters: This data will show if ANB033 can help patients with celiac disease. Positive results could boost investor confidence.
Supportive ifTop-line Phase 1b data for ANB033 in celiac disease is expected in Q4 2026.
Worry ifData shows no real change in celiac disease symptoms compared to placebo.
Why it matters: A smaller net loss would show better financial control and efficiency.
Supportive ifNet loss reported is less than $50.5 million in the next earnings report on August 11, 2026.
Worry ifNet loss increases beyond $50.5 million.
Why it matters: Finishing this could help further development. It may also confirm the pipeline's value.
Supportive ifCompletion of the Phase 1a trial for ANB101 is announced.
Worry ifTrial results show no effectiveness. This may lead to stopping work on the asset.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$365 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $832 loss on $10,000 · 8.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,519 loss on $10,000 · 35.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Financial results will show the company's cash use. They will also show how well it operates after the Spin-Off.
Watch forNet loss is smaller than in Q1 2026. This shows better financial management.
Also watch forNet loss goes up or stays high. This suggests ongoing financial problems.
Why it matters: Positive data would support the company's plans to advance ANB033 into Phase 2 trials. This could boost investor confidence.
Supportive ifManagement shares good results from the Phase 1b clinical trials for ANB033.
Worry ifPhase 1b data shows no big safety or effectiveness problems.
Why it matters: This data will show how well ANB033 prevents mucosal damage in celiac disease. Positive results could boost confidence in the drug's potential.
Supportive ifData from Cohort 1 shows strong prevention of mucosal damage.
Worry ifData from Cohort 1 does not show strong prevention of mucosal damage.
Why it matters: This data helps us understand mucosal healing in celiac disease. Good results could help ANB033.
Supportive ifData from Cohort 2 shows that mucosal healing worked well.
Worry ifData from Cohort 2 shows no strong mucosal healing.
Why it matters: Maintaining a strong cash position is crucial for ongoing trials. A decrease in cash could signal financial strain.
Worry ifCash and equivalents stay stable or increase. This shows strong financial health.
Less concerning ifCash and equivalents drop a lot. This raises concerns about funding.